glp 1 receptor agonist structure Human GLP-1 transmembrane domain in complex with allosteric modulators Structure and dynamics of semaglutide

That's comparable to or slightly above MedVi's pricing, so the value proposition isn't about saving money it's about what you get for the price

While obesity represents a profound public health issue to be sure, life and health insurers can create value for their clients and themselves by designing and implementing solutions to aid in preventing and slowing the progression of overweight, obesity, and associated chronic conditions

H.ReimannF.et al (2016)

The share of the public who report having heard about these drugs has increased since July 2023 when seven in ten adults reported having heard at least a little about these drugs and one in five (19%) said they had heard a lot. The share who say they have heard a lot about these drugs rises to at least four in ten among those who have ever been told by a doctor that they have diabetes (45%) or heart disease (41%) or have been told by a doctor in the past five years that they are overweight or obese (42%) the primary conditions these drugs are prescribed for

This is where Calocurb can play a supportive role